#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Transfusion and Haematology Today / 2024 - Ahead of Print

Primary mediastinal large B-cell lymphoma

Czech version

Authors: V. Hanáčková 1;  F. Folber 2;  L. Henzlová 3;  P. Flodr 4;  V. Procházka 1
Authors‘ workplace: Hemato-onkologická klinika LF UP a FN Olomouc 1;  Interní hematologická a onkologická klinika LF MU a FN Brno 2;  Klinika nukleární medicíny LF UP a FN Olomouc 3;  Ústav klinické a molekulární patologie, LF UP a FN Olomouc 4
Published in: Transfuze Hematol. dnes,30, 2024, No. Ahead of Print, p. 1-11.
Category: Review/Educational Papers
doi: https://doi.org/10.48095/cctahd2024prolekare.cz17

Overview

Primary mediastinal large B-cell lymphoma is an aggressive tumour characterized by a rapid increase of tumour mass in the anterior mediastinum that occurs in younger patients. Currently, in the age of immunochemotherapy, 5-year overall survival of patients is 80–90%. However, relapse occurs early, usually within one year from the end of therapy and the prognosis of these patients is unsatisfactory. Positron emission tomography combined with computed tomography using 18F-fluorodeoxyglucose is currently widely used not only at the time of diagnosis but also for monitoring response to treatment. The FDG PET/CT has a strong prognostic significance at the time of diagnosis, during treatment and after its termination. Maximum treatment efficacy and reduction of the long-term toxicity risk are key when selecting therapeutic modalities. Standard, anthracycline-based immunochemotherapy (R-CHOP, DA-EPOCH-R), autologous stem cell transplantation or consolidation radiotherapy for residual tumour mass are the current standard of the therapy. New modalities (PD1 inhibitors, brentuximab vedotin or CAR T cell therapy) are available, but require results from ongoing clinical trials to assess their effectivity.

Keywords:

radiotherapy – primary mediastinal large B-cell lymphoma – immunochemotherapy – positronemission tomography

Sources
    1. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117:5019–5032. https://doi.org/10.1182/blood-2011-01-293050.
    2. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours:lymphoid neoplasms. Leukemia. 2022;36:1720–1748. https://doi.org/10.1038/s41375-022-01620-2.
    3. Martelli M, Ferreri A, Di Rocco A, Ansuinelli M, Johnson PWM. Primary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol. 2017;113:318–327. https://doi.org/10.1016/j.crit revonc.2017.01.009.
    4. Addis BJ, Isaacson PG. Large cell lymphoma of the mediastinum: a B-cell tumour of probable thymic origin. Histopathology. 1986;10:379–390. https:/ / doi.org/ 10.1111/ j. 1365-2559.1986. tb02491.x.
    5. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–1392. https://doi.org/10.1182/blood.V84.5.1361.1361.
    6. Rüdiger T, Jaffe ES, Delsol G, et al. Workshop report on Hodgkin’s disease and related diseases (“grey zone” lymphoma). Ann Oncol Off J Eur Soc Med Oncol. 1998;9(Suppl 5):S31–S38. https://doi. org/10.1093/annonc/9.suppl_5.s31.
    7. Higgins JP, Warnke RA. CD30 expression is common in mediastinal large B-cell lymphoma. Am J Clin Pathol. 1999;112:241–247. https://doi. org/10.1093/ajcp/112.2.241.
    8. Dorfman DM, Shahsafaei A, Alonso MA. Utility of CD200 immunostaining in the diagnosis of primary mediastinal large B cell lymphoma: comparison with MAL, CD23, and other markers. Mod Pathol Off J U S Can Acad Pathol Inc. 2012;25:1637–1643. https://doi.org/10.1038/modpathol.2012.129.
    9. Rodig SJ, Savage KJ, LaCasce AS, et al. Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma. Am J Surg Pathol. 2007;31:106–112. https://doi. org/10.1097/01.pas.0000213334.40358.0e.
    10. Kim H-J, Kim HK, Park G, et al. Comparative pathologic analysis of mediastinal B-cell lymphomas: selective expression of p63 but no GATA3 optimally differentiates primary mediastinal large B-cell lymphoma from classic Hodgkin lymphoma. Diagn Pathol. 2019;14:133. https://doi. org/10.1186/s13000-019-0918-x.
    11. Wang Y, Wenzl K, Manske MK, et al. Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer J. 2019;9:73. https://doi. org/10.1038/s41408-019-0233-5.
    12. Prochazka V, Papajik T, Flodr P, et al. Programmed death-1 ligand is uniformly expressed on primary mediastinal diffuse large B-cell lymphoma cells with no influence on patient survival. Blood. 2012;120:2671. https:// doi.org/ 10.1182/ blood. V120.21.2671.2671.
    13. Twa DDW, Chan FC, Ben-Neriah S, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014;123:2062–2065. https://doi.org/10.1182/ blood-2013-10-535443.
    14. Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011;118:2659–2669. https://doi. org/10.1182/blood-2011-05-326538.
    15. Noerenberg D, Briest F, Hennch C, et al. Genetic characterization of primary mediastinal B-cell lymphoma: pathogenesis and patient outcomes. J Clin Oncol. 2024;42:452–466. https://doi. org/10.1200/JCO.23.01053.
    16. Jacobson JO, Aisenberg AC, Lamarre L, et al. Mediastinal large cell lymphoma: An uncommon subset of adult lymphoma curable with combined modality therapy. Cancer. 1988;62:1893–1898. https:/ / doi.org/ 10.1002/ 1097-0142(198811 01)62:9<1893::AID-CNCR2820620904>3.0.CO;2-X.
    17. Zinzani PL, Bendandi M, Frezza G, et al. Primary mediastinal B-cell lymphoma with sclerosis: clinical and therapeutic evaluation of 22 patients. Leuk Lymphoma. 1996;21:311–316. https://doi.org/10. 3109/10428199209067612.
    18. Johnson PWM, Davies AJ. Primary mediastinal B-cell lymphoma. Hematol Am Soc Hematol Educ Program. 2008:349–358. https:// doi. org/10.1182/asheducation-2008.1.349.
    19. Davnall F, Yip CSP, Ljungqvist G, et al. Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? Insights Imaging. 2012;3:573– 589. https:/ / doi. org/10.1007/s13244-012-0196-6.
    20. Pugachev A, Ruan S, Carlin S, et al. Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys. 2005;62:545–553. https://doi.org/10.1016/j.ijrobp.2005.02.009.
    21. Dunleavy K, Wilson WH. Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? Blood. 2015;125:33–39. https://doi. org/10.1182/blood-2014-05-575092.
    22. Nagle SJ, Chong EA, Chekol S, et al. The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma. Cancer Med. 2015;4:7–15. https:// doi. org/10.1002/cam4.322.
    23. Procházka V, Henzlová L, Buriánková E, et al. Prognostic impact of interim and final PET in primary mediastinal large B-cell lymphoma treated with intensive etoposide-based therapy. Blood. 2014;124:1729. https:// doi.org/ 10.1182/ blood. V124.21.1729.1729.
    24. Ceriani L, Martelli M, Zinzani PL, et al. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood. 2015;126:950–956. https://doi.org/10.1182/blood-2014-12-616474.
    25. Ceriani L, Martelli M, Conconi A, et al. Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study. Br J Haematol. 2017;178:588–591. https:// doi. org/10.1111/bjh.14728.
    26. Henzlová L, Koranda P, Procházka V, Papajík T, Zapletalová J. Využití interim 18F-FDG PET/CT pro prognostickou stratifikaci pacientů s primárním mediastinálním velkobuněčným B-lymfomem NuklMed. 2017;6:22–27.
    27. Mikhaeel NG, Smith D, Dunn JT, et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43:1209. https:// doi. org/10.1007/s00259-016-3315-7.
    28. van Velden FHP, Cheebsumon P, Yaqub M, et al. Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies. Eur J Nucl Med Mol Imaging. 2011;38:1636–1647. https:// doi. org/10.1007/s00259-011-1845-6.
    29. Ceriani L, Milan L, Martelli M, et al. Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. Blood. 2018;132:179–186. https://doi.org/10.1182/blood-2018-01-826958.
    30. Kurtz DM, Scherer F, Jin MC, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol. 2018;36:2845–2853. https:// doi. org/10.1200/JCO.2018.78.5246.
    31. Rivas-Delgado A, Nadeu F, Andrade-Campos M, et al. Cell-free DNA for genomic analysis in primary mediastinal large B-cell lymphoma. Diagnostics. 2022;12:1575. https://doi. org/10.3390/diagnostics12071575.
    32. Camus V, Viennot M, Lévêque E, et al. Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study. Leuk Lymphoma. 2022;63:834–844. https://doi.org/10.1080/10428194.2021.2010060.
    33. Todeschini G, Secchi S, Morra E, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer. 2004;90:372–376. https:// doi. org/10.1038/sj.bjc.6601460.
    34. Zinzani PL, Martelli M, Bertini M, et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica. 2002;87:1258–1264.
  2. Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted  EPOCH-Rituximab  therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368:1408–1416. https:// doi. org/10.1056/NEJMoa1214561.
  3. Giulino-Roth L, O’Donohue T, Chen Z, et al. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol. 2017;179:739–747. https://doi.org/10.1111/bjh.14951.
  4. Malenda A, Kołkowska-Leśniak A, Puła B, et al. Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma. Eur J Haematol. 2020;104:59–66. https://doi.org/10.11 11/ejh.13337.
  5. Shah NN, Szabo A, Huntington SF, et al. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018;180:534–544. https://doi.org/10.1111/ bjh.15051.
  6. Martelli M, Ceriani L, Zucca E, et al. 18F.fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J Clin Oncol. 2014;32:1769–1775. https:// doi. org/10.1200/JCO.2013.51.7524.
  7. Zucca E, Davies A, Kryachok I, et al. Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial. J Clin Oncol. 2023;41:LBA7505– LBA7505.  https:/ / doi.org/10.1200/JCO.2023.41.17_suppl.LBA7505.
  8. Hayden AR, Tonseth P, Lee DG, et al. Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach. Blood. 2020;136:2803–2811. https://doi. org/10.1182/blood.2019004296.
  9. Polgarova K, Janíková A, Belada D, et al. Survival of patients with primary mediastinal B-cell lymphoma treated by immunochemotherapy with or without radiotherapy. Blood. 2022;140:3831–3832. https://doi.org/10.1182/blood-2022-163113.
  10. Schmitz N, Zeynalova S, Nickelsen M, et al. CNS International prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34:3150–3156. https:// doi. org/10.1200/JCO.2015.65.6520.
  11. Papageorgiou SG, Diamantopoulos P, Levidou G, et al. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab. Hematol Oncol. 2013;31:10–17. https://doi. org/10.1002/hon.2012.
  12. Vassilakopoulos TP, Panitsas F, Mellios Z, et al. Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B-cell lymphoma in the rituximab era. Hematol Oncol. 2023;41:97–107. https:// doi. org/10.1002/hon.3096.
  13. Lewis KL, Jakobsen LH, Villa D, et al. High-dose methotrexate as CNS prophylaxis in high-risk aggressive B-cell lymphoma. J Clin Oncol. 2023;41:5376–5387. https://doi.org/10.1200/JCO.23.00365.
  14. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184–4190. https://doi.org/10.1200/JCO.2010.28.1618.
  15. Herrera AF, Chen L, Khajavian S, et al. Allogeneic stem cell transplantation provides durable remission in patients with primary mediastinal large B cell lymphoma. Biol Blood Marrow Transplant. 2019;25:2383–2387. https://doi.org/10.1016/j.bb mt.2019.07.041.
  16. Le Calvez B, Tessoullin B, Renaud L, et al. Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study. Acta Oncol. 2022;61:1332–1338. https://doi.org/1 0.1080/0284186X.2022.2130709.
  17. Armand P, Rodig S, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. J Clin Oncol. 2019;37:3291–3299. https:// doi. org/10.1200/JCO.19.01389.
  18. Zinzani PL, Thieblemont C, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood. 2023;142:141– 145. https:/ / doi.org/ 10.1182/ blood.2022019340.
  19. Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125:1394– 1402. https:/ / doi. org/10.1182/blood-2014-09-598763.
  20. Zinzani PL, Pellegrini C, Chiappella A, et al. Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Blood. 2017;129:2328–2330. https://doi. org/10.1182/blood-2017-01-764258.
  21. Svoboda J, Bair SM, Landsburg DJ, et al. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. Haematologica. 2020;106:1705–1713. https:// doi. org/10.3324/haematol.2019.238675.
  22. Zinzani PL, Santoro A, Gritti G, et al. Nivolumab combined with brentuximab vedotin for relapsed/ refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study. J Clin Oncol. 2019;37:3081–3089. https:// doi. org/10.1200/JCO.19.01492.
  23. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839–852. https:// doi. org/10.1016/S0140-6736(20)31366-0.
  24. Abramson JS, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141:1675–1684. https://doi. org/10.1182/blood.2022018730.
  25. Neelapu SS, Jacobson CA, Ghobadi A, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141:2307– 2315. https:/ / doi. org/10.1182/blood.2022018893.
  26. Bock AM, Nowakowski GS, Wang Y. Bispecific antibodies for non-Hodgkin lymphoma treatment. Curr Treat Options Oncol. 2022;23:155– 170. https://doi.org/10.1007/s11 864-021-00925-1.
  27. Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol. 2021;39:1959–1970. https:// doi. org/10.1200/JCO.20.03175.
  28. Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell– engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. 2023;41:2238–2247. https:// doi. org/10.1200/JCO.22.01725.

  29. PODÍL AUTORŮ NA PŘÍPRAVĚ RUKOPISU

    VH – příprava rukopisu

    FF – příprava kazuistiky a revize textu

    LH, PF – příprava obrazových podkladů a revize textu

    VP – léčba pacientů, revize textu, závěrečná kontrola rukopisu

    PODĚKOVÁNÍ

    Podpořeno granty: MZ ČR – RVO (FNOl, 00098892), IGA_LF_2024_001 a AZV NU21-03-00411.

    ČESTNÉ PROHLÁŠENÍ

    Autoři práce prohlašují, že v souvislosti s tématem, vznikem a publikací tohoto článku nejsou ve střetu zájmů a vznik ani publikace článku nebyly podpořeny žádnou farmaceutickou firmou.

    Do redakce doručeno dne: 3. 5. 2024.
    Přijato po recenzi dne: 4. 7. 2024.

    MUDr. Veronika Hanáčková
    Hemato-onkologická klinika LF UP a FN Olomouc
    Zdravotníků 248/7
    779 00 Olomouc
    e-mail:     veronika.hanackova@fnol.cz

Labels
Haematology Internal medicine Clinical oncology
Measuring factor VIII activity in patients with severe haemophilia A treated with extended half-life concen-trates – comparison of selected assay results
Article was published in

Transfusion and Haematology Today

Issue Ahead of Print
2024 Issue Ahead of Print
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#